Felodipine (FEL) is a vasoselective dihydropyridine calcium antagonist that has shown promising results in smaller congestive heart failure (CHF) studies. Angiotensin converting enzyme inhibitors (ACEI) are the cornerstone of CHF therapy, but many patients can not be treated with these drugs because of side effects or contraindications. We compared the effects of FEL. 10mg b.Ld., and enalapril (ENA), 10mg b.Ld., in a double blind, parallel study in 50 patients with CHF. At baseline and after 16 weeks treatment cardiopulmonary exercise test, neurohormone sampling, Holter recording and quality of life questionaires were assessed.PatientsFifty patients with CHF, NYHA class II–III, mean age 64±7 yr., mean LVEF of 26±9%, mean peak oxygen consump...
Several studies have shown symptomatic and haemodynamic improvement after the introduction of angiot...
AbstractObjectives. This study assessed the feasibility of an efficacy trial comparing angiotensin-c...
Background—We investigated the effects of candesartan (an angiotensin II antagonist) alone, enalapri...
Angiotensin-converting enzyme (ACE) inhibition is currently the cornerstone of congestive heart fail...
We evaluated the cardiopulmonary exercise test results before and after long-term (16 weeks) treatme...
Felodipine (FEL) is a vasoselective dihydropyridine calcium antagonist that has shown promising resu...
Hemodynamic effects of the new oral angiotensin-con-verting enzyme inhibitor, enalapril, were evalua...
Angiotensin-Converting enzyme inhibitors are effective vasodilators in the treatment of congestive h...
Background: We compared the angiotensin receptor–neprilysin inhibitor LCZ696 with enalapril in patie...
BACKGROUND: Clinical trials in heart failure have focused on the improvement in symptoms or decrease...
BACKGROUND: Clinical trials in heart failure have focused on the improvement in symptoms or decrease...
We performed a randomized double-blind placebo controlled cross-over study of enalapril in 16 patien...
If the cause of heart failure is atrial fibrillation, irregular beating of the heart, the first choi...
Converting enzyme inhibition of the renin-angiotensin system has proved a valuable therapeutic appro...
BACKGROUND: We compared the angiotensin receptor-neprilysin inhibitor LCZ696 with enalapril in pati...
Several studies have shown symptomatic and haemodynamic improvement after the introduction of angiot...
AbstractObjectives. This study assessed the feasibility of an efficacy trial comparing angiotensin-c...
Background—We investigated the effects of candesartan (an angiotensin II antagonist) alone, enalapri...
Angiotensin-converting enzyme (ACE) inhibition is currently the cornerstone of congestive heart fail...
We evaluated the cardiopulmonary exercise test results before and after long-term (16 weeks) treatme...
Felodipine (FEL) is a vasoselective dihydropyridine calcium antagonist that has shown promising resu...
Hemodynamic effects of the new oral angiotensin-con-verting enzyme inhibitor, enalapril, were evalua...
Angiotensin-Converting enzyme inhibitors are effective vasodilators in the treatment of congestive h...
Background: We compared the angiotensin receptor–neprilysin inhibitor LCZ696 with enalapril in patie...
BACKGROUND: Clinical trials in heart failure have focused on the improvement in symptoms or decrease...
BACKGROUND: Clinical trials in heart failure have focused on the improvement in symptoms or decrease...
We performed a randomized double-blind placebo controlled cross-over study of enalapril in 16 patien...
If the cause of heart failure is atrial fibrillation, irregular beating of the heart, the first choi...
Converting enzyme inhibition of the renin-angiotensin system has proved a valuable therapeutic appro...
BACKGROUND: We compared the angiotensin receptor-neprilysin inhibitor LCZ696 with enalapril in pati...
Several studies have shown symptomatic and haemodynamic improvement after the introduction of angiot...
AbstractObjectives. This study assessed the feasibility of an efficacy trial comparing angiotensin-c...
Background—We investigated the effects of candesartan (an angiotensin II antagonist) alone, enalapri...